Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v26.i41.6455

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6179)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-7) series.

Item

Count

PDF

326

WORD

170

HTML

3212

Figures (1-2)

252

Tables (1-7)

161

Sum=4121

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

550

Download

1508

Sum=2058

Nov 7, 2020 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455

Full Size Figure Download Figure

Figure 2 Impact of key model variables on the cost-effectiveness of infliximab maintenance therapy relative to conventional maintenance therapy for moderate to severe Crohn’s disease in one-way sensitivity analyses. CD: Crohn’s disease; CMT: Conventional maintenance therapy; ICER: Incremental cost-effectiveness ratio; IMT: Infliximab maintenance therapy.

Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455